CH Biotech R&D Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Wen Ren Chen
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 7.6yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Solid Earnings May Not Tell The Whole Story For CH Biotech R&D (TWSE:6534)
Mar 10
CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt
Apr 05A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns
Mar 18Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Feb 09
Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture
Jan 11Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?
Dec 15Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield
Nov 24CEO
Wen Ren Chen
no data
Tenure
Wen Ren Chen is Manager of CH Biotech R&D Co. Ltd.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Manager | no data | no data | no data | |
| Assistant Vice President of Finance Department | 7.7yrs | no data | no data | |
| Accounting Supervisor | no data | no data | no data | |
| Chief of Board Office | 7.6yrs | no data | 0.056% NT$ 4.4m | |
| Head of R&D Department | 5.4yrs | no data | no data |
7.6yrs
Average Tenure
Experienced Management: 6534's management team is seasoned and experienced (7.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 11.5yrs | no data | 19.61% NT$ 1.5b | |
| Director | 6.9yrs | no data | 0.15% NT$ 11.9m | |
| Director | 4.7yrs | no data | no data | |
| Independent Director | 3.7yrs | no data | no data | |
| Institutional Director | 2yrs | no data | no data | |
| Independent Director | no data | no data | no data | |
| Independent Director | no data | no data | no data | |
| Director | 1.3yrs | no data | 0.16% NT$ 12.3m | |
| Director | 1.3yrs | no data | no data |
3.7yrs
Average Tenure
Experienced Board: 6534's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/02 23:34 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CH Biotech R&D Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Hsiu Chi Lin | Masterlink Securities Corp. |